Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression

Oncogene

Volumn 30, Issue 39, 2011, Pages 4129-4140

  Giordano, C ^a   Catalano, S ^a   Panza, S ^a   Vizza, D ^a   Barone, I ^a   Bonofiglio, D ^a   Gelsomino, L ^a   Rizza, P ^a   Fuqua, S A W ^b   Ando S ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

breast cancer; FXR; HER2; NF kB; tamoxifen resistance

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; BETA ACTIN; CHENODEOXYCHOLIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FARNESOID X RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P42; PROTEIN P44; TAMOXIFEN;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; CELL STRAIN MCF 7; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE INCREASE; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHENODEOXYCHOLIC ACID; CHROMATIN IMMUNOPRECIPITATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ELECTROPHORETIC MOBILITY SHIFT ASSAY; EPIDERMAL GROWTH FACTOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOXAZOLES; MITOGEN-ACTIVATED PROTEIN KINASE 3; NF-KAPPA B; PROMOTER REGIONS, GENETIC; RECEPTOR, ERBB-2; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 80053308099     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.124     Document Type: Article

References (49)

1. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW et al. (1992). Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 23: 974-979.
2. Ananthanarayanan M, Balasubramanian N, Makishima M, Mangels-dorf DJ, Suchy FJ. (2001). Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem 276: 28857-28865.
3. Andrews NC, Faller DV. (1991). A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 19: 2499.
4. Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK et al. (2004). HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 10: 5670-5676. (Pubitemid 39180941)
5. Arpino G, Wiechmann L, Osborne CK, Schiff R. (2008). Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29: 217-233. (Pubitemid 351519691)
6. Barone I, Brusco L, Gu G, Selever J, Beyer A, Covington KR et al. (2011). Loss of Rho GDI a and resistance to tamoxifen via effects on estrogen receptor a. Journal Natl Cancer Inst (in press).
7. Barone I, Cui Y, Herynk MH, Corona-Rodriguez A, Giordano C, Selever J et al. (2009). Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway. Cancer Res 69: 4724-4732.
8. Bishop-Bailey D. (2004). FXR as a novel therapeutic target for vascular disease. Drug News Perspect 17: 499-504. (Pubitemid 39642725)
9. Blume-Jensen P, Hunter T. (2001). Oncogenic kinase signalling. Nature 411: 355-365. (Pubitemid 32467045)
10. Catalano S, Malivindi R, Giordano C, Gu G, Panza S, Bonofiglio D et al. (2010). Farnesoid X receptor, through the binding with steroidogenic factor 1-responsive element, inhibits aromatase expression in tumor Leydig cells. J Biol Chem 285: 5581-5593.
11. Chung YL, Sheu ML, Yang SC, Lin CH, Yen SH. (2002). Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. Int J Cancer 97: 306-312.
12. Claudel T, Sturm E, Duez H, Torra IP, Sirvent A, Kosykh V et al. (2002). Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest 109: 961-971. (Pubitemid 34275117)
13. De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F et al. (2005). A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 11: 4741-4748. (Pubitemid 41557193)
14. Encarnacion CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SA, Osborne CK. (1993). Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 26: 237-246. (Pubitemid 23304239)
15. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM et al. (1998). Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388. (Pubitemid 28439961)
16. Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T et al. (1995). Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81: 687-693.
17. Giordano C, Cui Y, Barone I, Ando S, Mancini MA, Berno V et al. (2010). Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305. Breast Cancer Res Treat 119: 71-85.
18. Glockner S, Lehmann U, Wilke N, Kleeberger W, Langer F, Kreipe H. (2001). Amplification of growth regulatory genes in intraductal breast cancer is associated with higher nuclear grade but not with the progression to invasiveness. Lab Invest 81: 565-571. (Pubitemid 32298802)
19. Gradishar WJ. (2004). Tamoxifen-what next? Oncologist 9: 378-384.
20. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC et al. (2005). Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 23: 2469-2476. (Pubitemid 47050837)
21. He F, Li J, Mu Y, Kuruba R, Ma Z, Wilson A et al. (2006). Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ Res 98: 192-199.
22. Herynk MH, Beyer AR, Cui Y, Weiss H, Anderson E, Green TP et al. (2006). Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells. Mol Cancer Ther 5: 3023-3031. (Pubitemid 46092043)
23. Hurst HC. (2001). Update on HER-2 as a target for cancer therapy: the ERBB2 promoter and its exploitation for cancer treatment. Breast Cancer Res 3: 395-398. (Pubitemid 34196367)
24. Ishii S, Imamoto F, Yamanashi Y, Toyoshima K, Yamamoto T. (1987). Characterization of the promoter region of the human c-erbB-2 protooncogene. Proc Natl Acad Sci USA 84: 4374-4378. (Pubitemid 17097838)
25. Johnston SR. (2009). Enhancing the efficacy of hormonal agents with selected targeted agents. Clin Breast Cancer 9(Suppl 1): S28-S36.
26. Journe F, Laurent G, Chaboteaux C, Nonclercq D, Durbecq V, Larsimont D et al. (2008). Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation. Breast Cancer Res Treat 107: 49-61. (Pubitemid 350179595)
27. Kalaany NY, Mangelsdorf DJ. (2006). LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol 68: 159-191.
28. Kirkegaard T, McGlynn LM, Campbell FM, Muller S, Tovey SM, Dunne B et al. (2007). Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifen-treated breast cancer patients. Clin Cancer Res 13: 1405-1411. (Pubitemid 46450429)
29. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME et al. (2003). Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144: 1032-1044. (Pubitemid 36262870)
30. Kocarek TA, Shenoy SD, Mercer-Haines NA, Runge-Morris M. (2002). Use of dominant negative nuclear receptors to study xenobiotic-inducible gene expression in primary cultured hepato-cytes. J Pharmacol Toxicol Methods 47: 177-187. (Pubitemid 36287358)
31. Laffitte BA, Kast HR, Nguyen CM, Zavacki AM, Moore DD, Edwards PA. (2000). Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J Biol Chem 275: 10638-10647. (Pubitemid 30202131)
32. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A et al. (1999). Identification of a nuclear receptor for bile acids. Science 284: 1362-1365. (Pubitemid 29289663)
33. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S et al. (2004). HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 101: 9393-9398. (Pubitemid 38812885)
34. Morelli C, Garofalo C, Sisci D, del Rincon S, Cascio S, Tu X et al. (2004). Nuclear insulin receptor substrate 1 interacts with estrogen receptor alpha at ERE promoters. Oncogene 23: 7517-7526. (Pubitemid 39389693)
35. Nicholson RI, Staka C, Boyns F, Hutcheson IR, Gee JM. (2004). Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocr Relat Cancer 11: 623-641. (Pubitemid 40065542)
36. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA et al. (2003). Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95: 353-361. (Pubitemid 36395255)
37. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA et al. (1999). Bile acids: natural ligands for an orphan nuclear receptor. Science 284: 1365-1368. (Pubitemid 29289664)
38. Sabnis GJ, Jelovac D, Long B, Brodie A. (2005). The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res 65: 3903-3910. (Pubitemid 40616372)
39. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. (2004). Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 10: 331S-336S. (Pubitemid 38116639)
40. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A et al. (2001). Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19: 2587-2595. (Pubitemid 32441364)
41. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H et al. (2004). Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96: 926-935. (Pubitemid 38868139)
42. Sirianni R, Chimento A, Malivindi R, Mazzitelli I, Ando S, Pezzi V. (2007). Insulin-like growth factor-I, regulating aromatase expression through steroidogenic factor 1, supports estrogen-dependent tumor Leydig cell proliferation. Cancer Res 67: 8368-8377. (Pubitemid 47395176)
43. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712. (Pubitemid 19147683)
44. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792. (Pubitemid 32222155)
45. Staka CM, Nicholson RI, Gee JM. (2005). Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model. Endocr Relat Cancer 12(Suppl 1): S85-S97. (Pubitemid 41395416)
46. Swales KE, Korbonits M, Carpenter R, Walsh DT, Warner TD, Bishop-Bailey D. (2006). The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res 66: 10120-10126. (Pubitemid 44672066)
47. Vavassori P, Mencarelli A, Renga B, Distrutti E, Fiorucci S. (2009). The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol 183: 6251-6261.
48. Xing X, Wang SC, Xia W, Zou Y, Shao R, Kwong KY et al. (2000). The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nat Med 6: 189-195. (Pubitemid 30082364)
49. Yarden Y. (2001). Biology of HER2 and its importance in breast cancer. Oncology 61(Suppl 2): 1-13. (Pubitemid 33033419)